Evogene Reports Q3 2026 Results, Advances Drug and Fungicide Programs
Evogene highlights progress in its aGVHD drug discovery and AgPlenus fungicide programs as it releases third-quarter and nine-month financial results.
Evogene Ltd., the Israeli computational biology company listed on both Nasdaq and the Tel Aviv Stock Exchange, released its financial results for the third quarter and first nine months of 2026, underscoring momentum in two internally developed programs that the company views as central to its long-term growth strategy.
The first program targets acute graft-versus-host disease, a severe and often life-threatening complication that can arise following stem cell transplantation. Evogene's drug discovery effort in this space leverages its proprietary computational platforms to identify novel therapeutic candidates, an approach the company says differentiates it from conventional pharmaceutical research methods.
Read more Inverse Anthropic ETFs Offer Bears a Way to Bet Against ANT →
The second area of focus involves AgPlenus, Evogene's agricultural biologicals subsidiary, which is working to discover a fungicide with a novel mode of action directed against Septoria, a fungal pathogen responsible for significant crop losses in wheat and other staple grains worldwide. A new mode of action would be particularly valuable to the agricultural sector, where resistance to existing fungicide classes has become an escalating concern for farmers and agrochemical developers alike.
Evogene has built its business model around deploying artificial intelligence and machine learning tools to accelerate discovery timelines across both human health and agriculture, sectors that share the underlying challenge of identifying effective biological compounds at scale. The dual-program update signals the company's intent to advance multiple pipelines in parallel rather than concentrate resources on a single therapeutic or agrochemical candidate.
Full details of the quarterly financial figures and program milestones were disclosed in the company's official release. Continue reading at Earnings.